We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
KINAXO Receives 1M Euro Funding to Quantify Drug Interactions with Cellular Protein Targets
News

KINAXO Receives 1M Euro Funding to Quantify Drug Interactions with Cellular Protein Targets

KINAXO Receives 1M Euro Funding to Quantify Drug Interactions with Cellular Protein Targets
News

KINAXO Receives 1M Euro Funding to Quantify Drug Interactions with Cellular Protein Targets

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "KINAXO Receives 1M Euro Funding to Quantify Drug Interactions with Cellular Protein Targets"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

KINAXO Biotechnologies GmbH has announced that it has received research funding of about € 1 million from the German Ministry for Education and Research (BMBF). This will enable KINAXO to establish a universally applicable technology platform to quantify small molecule-protein interactions in mammalian tissues and cell lines.

Implementation of the new technologies will be supported by two experts, Dr. Lothar Jansch of the Helmholtz Institute in Braunschweig and Dr. Henrik Daub of the Max Planck Institute for Biochemistry in Martinsried.

Klaus Godl, KINAXO’s Head of Research says: "Combining quantitative mass spectrometry with the KinaTorTM technology significantly strengthens our chemical proteomics capabilities. With this new set-up we can immediately distinguish relevant drug-protein interactions from weak binding as well as determine a compound’s affinity without the need of in vitro assays. Having a proven track record as a kinase specialist we will now start to analyse the target profiles of other inhibitor classes such as protease and phosphatase inhibitors as well as drugs that failed in the clinic due to off-target effects."

Advertisement